Report Archive
All Research
Page 34 of 52 · 1238 reports
43/100
24Buffett
First Solar: A Deep Value-Investing Analysis
The leading U.S. thin-film solar manufacturer, whose order visibility, net-cash balance sheet and scarce policy position are all genuine advantages; but roughly $1.6 billion of 45X credits in 2025 all but dictated the level of reported earnings, and at the current $273.67 the stock already sits close to the optimistic scenario, with an ideal buy range of $140-185.
44/100
53Buffett
Tapestry: A Deep-Dive Investment Study
A Coach-driven brand group whose cash flow has improved markedly and whose capital allocation is turning rational, but at $139 the stock already sits at the upper-middle of fair value with no obvious margin of safety; rated Watch, with an ideal buy range of $95-115.
45/100
53Buffett
IQVIA Holdings: A Deep-Dive Value Investing Study
IQVIA is the leading life-sciences infrastructure platform, with steady FCF, a diversified client base, and a composite moat. At $165.62 the stock sits near the top of the conservative valuation range and the bottom of the fair range, leaving a thin margin of safety; the ideal buy range is $140-155.
42/100
67Buffett
Super Micro Computer, a Zen Horizon Study: High AI-Server Torque Alongside a Governance Discount
Super Micro is an AI-server and rack-scale infrastructure integrator riding still-strong demand, with full-year revenue guidance of $38.9-40.4 billion. But gross margin has slid from 18% to 11%, nine-month operating cash flow is -$7.56 billion, the internal-control material weakness remains unremediated, and an export-control criminal case has resurfaced. At about $38.19 the stock earns a Watch rating, with a fair buy range of $28-33.
47/100
66Buffett
VeriSign From a Long-Term Owner's Perspective
VeriSign is a high-quality internet infrastructure franchise built around .com and .net registry economics. Its moat is strong and its cash flow is exceptional, but the current valuation already prices in much of that certainty. Research rating Watch: a durable compounder, yet the ideal buy zone is $180 to $220 rather than the current price.
41/100
Global Payments: Valuation Rerating Study After the Transition to a Pure-Play Merchant Platform
A pure-play merchant payments platform after completing the Worldpay acquisition and the Issuer Solutions divestiture. At $73.46, the stock trades at roughly 5.3x the midpoint of 2026 adjusted EPS, with a fair buy range of $65-78.
43/100
84Buffett
Allison Transmission: A Reassessment During the Integration Phase
The legacy Allison business is a rare industrial cash cow whose margins were validated through a weak cycle; after absorbing Dana Off-Highway in 2026, the company's character shifts from a pure cash cow into an integration platform. At roughly 17x PE the stock is neither cheap nor expensive, with a fair buy range of $95-108. Rating Hold: the core is still a rare industrial cash cow, but integration must be proven before any valuation re-rating.
43/100
Teledyne Technologies (TDY): A Long-Term Owner's Perspective
A multi-segment industrial-technology platform with solid cash-flow quality and cross-cycle resilience. But at $704 the stock already sits at the upper edge of an optimistic valuation, leaving conservative buyers without a margin of safety; the ideal buy-in range is $400-500. Rating Watch: a good company at too rich a price.
47/100
56Buffett
Incyte Zen Horizon Analysis Report
Incyte is a commercial-stage biopharma company with strong cash flow but an unproven post-Jakafi transition. The core debate is whether Opzelura, Niktimvo, Monjuvi/Minjuvi, Zynyz, and the late-stage pipeline can offset real 2028 patent pressure while preserving earnings power. Report rating Watch: at $97, the stock lacks enough margin of safety relative to a fair buy range of $80-88.
51/100
99Buffett
ResMed: A Long-Term Owner's Perspective
A high-quality, cash-generative, net-cash leader in sleep and respiratory health, but at roughly $206 the stock looks more like a good company near fair value than a bargain, with a thin margin of safety; ideal buy range $170-190. Rating Watch: a durable compounder priced for quality, not for safety of margin.
45/100
45Buffett
FIS: A Contrarian Study of a Financial-Infrastructure Cash Cow in Transition
A financial-infrastructure platform combining bank core systems, capital-markets back office, and newly acquired issuer processing. The market still prices FIS off the Worldpay failure; at $42.02 the shares trade at roughly 7.3x trailing PE, with an ideal buy range of $38-45.
48/100
78Buffett
Fair Isaac: A Long-Term Owner's View
FICO is a high-quality scoring franchise embedded in the U.S. credit system. The core thesis is that Scores remains a powerful, high-margin business, but the current price of $1,278 has pulled forward too much of the optimistic case and leaves too little margin of safety versus an ideal buy range of $550-$700. Rating Watch: the business deserves close long-term tracking, but today's valuation does not support aggressive new buying.
46/100
Long-Term Research on Waters' Laboratory Analytics and Diagnostic Tools
Waters sells liquid chromatography, mass spectrometry, thermal analysis, software, consumables, and services, and after acquiring BD Biosciences it has become a life-sciences and diagnostics platform. At $342, the stock is already close to the optimistic valuation band, while the ideal buy range is $200-240. Rating Watch: a high-quality business, but current pricing leaves too little margin of safety before integration and cash-flow proof improve.
46/100
VICI Properties Experiential Real Estate REIT Long-Term Research
VICI Properties is a U.S. and Canadian experiential real estate REIT owning landmark gaming properties leased to Caesars, MGM, Venetian, and other operators under ultra-long triple-net leases. At $28.63, the stock trades at roughly 11.7x 2026 AFFO with a dividend yield of about 6.3%, while the ideal buy range is $25-29. Research rating Cautious Buy: a high-quality, high-visibility income asset, but tenant concentration and capital-allocation risks require price discipline.
43/100
77Buffett
Raymond James: A Long-Term Study of a Diversified Financial-Services Platform
A diversified financial platform spanning wealth management, investment banking, asset management, and banking, with PCG making up 68% of net revenue. At $145 the stock trades at roughly 13.7x TTM P/E, placing it in a fair-to-neutral range rather than clearly undervalued. Ideal buy range: $105–125.
43/100
59Buffett
Northern Trust: A Study of Custody-Banking and Wealth-Management Infrastructure
A high-quality financial-infrastructure company spanning global custody, wealth management, and asset servicing. At $167.94 the stock trades at 2.57x PB and 17.6x PE, so the margin of safety is thin, with an ideal buy range of $105–125. Rating Watch: a good business, but not a good price.
39/100
37Buffett
DTE Energy: A Long-Term Owner's Perspective on a U.S. Regulated Utility
DTE Energy is a Michigan regulated utility spanning electricity, natural gas, and non-utility commercial energy segments. The business is understandable and earnings are steady, but the $145 share price already sits in a fair-to-rich valuation range. Research rating Watch: the ideal buy range is $90-110.
47/100
Fiserv Contrarian Research After the Reset in Payments and Financial Infrastructure
Fiserv is a financial infrastructure leader spanning bank core systems, Clover merchant acquiring, and global payment networks. After guidance cuts and a crisis of trust, the stock at $55.62 trades at roughly 9x forward owner earnings, with an ideal buy range of $45-60. Rating Cautious Buy: the thesis rests on durable cash flows, a clear valuation discount, and successful margin repair after the 2025 reset.
45/100
Martin Marietta: A Long-Term Owner's Study of the U.S. Aggregates Leader
The second-largest U.S. aggregates producer, a regional oligopolist built on scarce quarries and roughly 85-year reserve lives. Its headline 13.7x PE is distorted by a one-off 2026 Q1 discontinued-operations gain; on Owner Earnings it actually trades at 33-38x, and the $574 price already discounts the optimistic case. Rating Watch: a fine business, but likely not a good price today.
40/100
Extra Space Storage: A Long-Term Owner's View of a Self-Storage Platform REIT
America's largest self-storage management company; 2026Q1 same-store NOI grew +1.2%, recovering from a period of supply pressure. The 4.5% dividend yield roughly matches the 10-year Treasury, and the current price of $144 sits in the middle-to-upper portion of the fair value range; the fair buy range is $110-125.
39/100
M&T Bank: A Long-Term Owner's Perspective on a U.S. Regional Bank
M&T Bank posts a 2025 ROTCE of 15.36%, an NPL ratio of 0.89%, and CET1 of 10.33%, each ahead of peers. Yet at 1.85x P/TBV it trades with no meaningful discount to USB or TFC. Rating Watch: the $215 share price is a fair price for a good bank, not a cheap trade, with an ideal entry range of $165-185.
40/100
Estée Lauder: Premium Beauty Brand Equity Restoration Study
Revenue fell a cumulative -19% from FY2022 to FY2025 with an FY2025 operating loss of $785 million; the business is recovering through the first nine months of FY2026, but the $91.20 share price already sits near the optimistic valuation of $91/share — the fair buy range of $45-55 requires a 25%-35% margin of safety.
45/100
59Buffett
SANY Heavy Industry Re-rating: A Globalized Construction-Machinery Leader on Overseas Delivery Plus Domestic Recovery
With overseas revenue at 64% of sales and a 31.7% international gross margin, SANY has moved from a laggard on China's property chain to a globalized heavy-equipment platform running on domestic recovery plus overseas delivery. A TTM P/E of about 20x already reflects the structural improvement, leaving a fair buy range of 15.5–17 yuan. Rated Hold: a good company, but the price has already priced in much of the recovery.
47/100
84Buffett
Zoetis Long-Term Business Owner Value Analysis
Zoetis is the global leader in animal health, with roughly 300 product lines, 2025 revenue of $9.467 billion, gross margin of 71.8%, ROIC of about 29%, and FCF of $2.283 billion. The core thesis is a high-quality, cash-generative animal health compounder whose valuation has fallen to a reasonable-to-low range, although the -11% decline in U.S. companion animal revenue in Q1 2026 is a real crack to monitor. Research rating Cautious Buy: a durable business near fair value, suitable for disciplined staged entry rather than an aggressive full position.